4.8 Article

Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing

Journal

THERANOSTICS
Volume 11, Issue 20, Pages 9967-9987

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/thno.63995

Keywords

Brca1/BRCA1; single cell RNA-seq; tumor heterogeneity; mammary tumor; Mrc2

Funding

  1. National Natural Science Foundation of China [81602587]
  2. Chair Professor Grant [CPG2019-00019-FHS, CPG2021-00021-FHS]
  3. Macao Science and Technology Development Fund (FDCT) [065/2015/A2, 0011/2019/AKP, 0034/2019/AGJ]
  4. FDCT [0004/2019/AFJ]
  5. Guangdong Science and Technology Department [2020A050515005]

Ask authors/readers for more resources

The study identified four subtypes of BRCA1 deficient mammary tumors with distinct molecular features and different sensitivities to anti-cancer drugs at the intertumor level, as well as heterogeneous subgroups within the tumors mainly based on different activities of cell proliferation, DNA damage response/repair and epithelial-to-mesenchymal transition (EMT). Furthermore, through pseudo-temporal analysis of scRNA-seq data, the study reconstructed the transcriptome alterations during BRCA1 related mammary tumorigenesis and discovered an oncogene Mrc2 that could reduce mammary tumor growth in vitro and in vivo.
Background: BRCA1 plays critical roles in mammary gland development and mammary tumorigenesis. And loss of BRCA1 induces mammary tumors in a stochastic manner. These tumors present great heterogeneity at both intertumor and intratumor levels. Methods: To comprehensively elucidate the heterogeneity of BRCA1 deficient mammary tumors and the underlying mechanisms for tumor initiation and progression, we conducted bulk and single cell RNA sequencing (scRNA-seq) on both mammary gland cells and mammary tumor cells isolated from Brca1 knockout mice. Results: We found the BRCA1 deficient tumors could be classified into four subtypes with distinct molecular features and different sensitivities to anti-cancer drugs at the intertumor level. Whereas within the tumors, heterogeneous subgroups were classified mainly due to the different activities of cell proliferation, DNA damage response/repair and epithelial-to-mesenchymal transition (EMT). Besides, we reconstructed the BRCA1 related mammary tumorigenesis to uncover the transcriptomes alterations during this process via pseudo-temporal analysis of the scRNA-seq data. Furthermore, from candidate markers for BRCA1 mutant tumors, we discovered and validated one oncogene Mrc2, whose loss could reduce mammary tumor growth in vitro and in vivo. Conclusion: Our study provides a useful resource for better understanding of mammary tumorigenesis induced by BRCA1 deficiency.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available